Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Mycal CaseyLorriane OdhiamboNidhi Aggarwal Mahran Shoukier Jamani B GarnerK M IslamJorge E Cortes

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

There are significant demographic and geographic under-representation and imbalances in pivotal CTs leading to drug approvals for leukemias and MM compared with the population affected. These disparities need to be addressed to make results applicable to all relevant populations.

Keyphrases

clinical trial
multiple myeloma
cross sectional
emergency department
electronic health record
drug administration
neural network
double blind